• COAPT: Mortality or Rehospitalization Remains Significantly Lower for MitraClip over Optimal Medical Therapy at 3 Years

    SAN FRANCISCO – MitraClip’s lower rates of mortality and heart failure rehospitalization over optimal medical therapy remained significant at 3 years, according to the latest COAPT trial results presented Saturday at Transcatheter Cardiovascular Therapeutics 2019.

    The cumulative incidence of all-cause death or heart failure rehospitalization at 3 years was 58.8% in the MitraClip plus maximally tolerated guideline-directed medical therapy (GDMT) and 88.1% for GDMT alone (p<0.001).  The number needed to treat to see benefit is 3.4 patients (95% confidence interval, 2.7, 4.6], according to data presented by Michael Mack, MD, of The Heart Hospital Baylor Plano, Plano, Texas.

    The COAPT trial randomized 614 symptomatic heart failure patients with moderate-to-severe or severe secondary mitral regurgitation (MR) on maximally tolerated medical therapy.  Patients in the GDMT-alone arm were allowed to cross over to MitraClip (Abbott) after they passed the 24-month trial follow-up time period. At that time, 18.6% of the eligible patients crossed over.  Patients not eligible to cross over included those who died, received a heart transplant or who were implanted with a left ventricular assist device.

    The rate of mortality or heart failure rehospitalization following crossover was 28% at approximately 12 months. Panelists at a press conference announcing the results noted that this 1-year mortality rate was similar to that of patients who received the MitraClip to begin with, showing that even a late MitraClip implantation provided benefit for study patients on GDMT alone who survived for two years without the device.

    This study was funded by Abbott. 

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details